预约演示
更新于：2025-06-04
Fenretinide
芬维A胺
更新于：2025-06-04
概要
基本信息
最高研发阶段临床2/3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C26H33NO2 |
InChIKeyAKJHMTWEGVYYSE-FXILSDISSA-N |
CAS号65646-68-6 |
关联
36
项与 芬维A胺 相关的临床试验NCT06922539
A Phase 1a/1b Trial in Relapsed/Refractory Small Cell Lung Cancer to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
开始日期2025-06-01 |
申办/合作机构- |
NCT04234048
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
开始日期2023-12-18 |
申办/合作机构- |
NCT06181760
A Phase 1a, Randomized, Double-blind Placebo-controlled Study to Evaluate Safety and Tolerability and to Characterize the Pharmacokinetic Profile of Single Ascending Doses of Fenretinide Oral Capsules in Healthy Adult Volunteers
The goal of this clinical trial was to learn about a single dose of fenretinide in healthy volunteers, in both a fasted and fed state. The main questions to answer were:
* How well is a single dose of fenretinide tolerated? AND
* How is a single dose of fenretinide metabolized in healthy volunteers?
Participants will be asked to:
* Remain confined in a clinical research unit for 5 days after dosing.
* Provide blood samples for intense PK sampling and safety labs.
* Fast for 10 hours prior to administration of study drug (fasted cohorts).
* Consume a high fat meal prior to administration of study drug (fed cohort).
* Return to the clinic for a single follow-up visit for safety assessments.
The study will compare active fenretinide to placebo to see if fenretinide is more or less tolerable than placebo.
* How well is a single dose of fenretinide tolerated? AND
* How is a single dose of fenretinide metabolized in healthy volunteers?
Participants will be asked to:
* Remain confined in a clinical research unit for 5 days after dosing.
* Provide blood samples for intense PK sampling and safety labs.
* Fast for 10 hours prior to administration of study drug (fasted cohorts).
* Consume a high fat meal prior to administration of study drug (fed cohort).
* Return to the clinic for a single follow-up visit for safety assessments.
The study will compare active fenretinide to placebo to see if fenretinide is more or less tolerable than placebo.
开始日期2023-11-22 |
申办/合作机构 |
100 项与 芬维A胺 相关的临床结果
登录后查看更多信息
100 项与 芬维A胺 相关的转化医学
登录后查看更多信息
100 项与 芬维A胺 相关的专利（医药）
登录后查看更多信息
1,514
项与 芬维A胺 相关的文献（医药）2025-03-01·Journal of Cosmetic Dermatology
A Functional Skincare Formulation Mixed With Retinyl Propionate, Hydroxypinacolone Retinoate, and Vitamin C on Antiaging and Whitening Han Women in Shanghai, China
Article
作者: Qiao, Jian ; Chen, Min ; Bian, Qianjin ; Zhang, Fan ; Fang, Wei
ABSTRACT:
Background:
Human skin is remodeled as a result of aging. Retinoids (or retinol derivatives) can intervene in this process, which can be optimally formulated and concentrated by providing maximum antiaging effects with minimal irritation.
Aims:
To determine the optimal ratio of two retinol derivatives hydroxypinacolone retinoate (HPR), retinol propionate (RP), and vitamin C (VitC) in dermal remodeling and preventing skin aging, and to investigate their synergistic antiaging and whitening effects in vitro and in vivo.
Methods:
An in vitro model of human skin fibroblast (HSF) was established to evaluate the cellular viability of VitC and/or RP/HPR treatment. We quantified the expression of genes associated with antiaging and retinol receptors in HSFs treated with VitC and/or RP/HPR. The research was conducted on 120 volunteer women to quantify the antiaging efficacy of functional skincare formulation.
Results:
A combination of VitC and RP/HPR at a weight ratio of 40:3 achieved the optimal and safe antiaging performance in vitro. Transcription of aging‐associated genes and the release of elastin and senescence‐associated secretory phenotypes (SASPs) increased significantly after UV irradiation, whereas VitC and RP/HPR cotreatment can inhibit this increase. The synergistic stimulation of VitC and RP/HPR cotreatment showed higher efficacy in the recovery ability of skin injury.
Conclusions:
Our results indicated the advanced skin antiaging and whitening effects of VitC and RP/HPR cotreatment in vitro and in vivo. A combination of VitC and RP/HPR is a potent strategy to postpone skin aging and improve skin whitening for middle‐aged women.
Trial Registration:
ClinicalTrials.gov identifier: 2020‐LS‐023
2025-01-01·Journal of Cystic Fibrosis
Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis
Article
作者: Zuckerman, Jonathan B ; Colin, Patrick ; Konstan, Michael W ; Kianicka, Irenej ; Middleton, Peter G ; Kotsimbos, Tom ; Radzioch, Danuta ; Polineni, Deepika ; Matouk, Elias ; Lands, Larry C ; Liou, Theodore G ; Houle, Jean-Marie ; Chmiel, James F ; Pislariu, Radu ; Potvin, Diane ; Bilodeau, Lara ; Nasr, Samya Z
BACKGROUND:
Lung inflammation is associated with tissue damage in cystic fibrosis (CF). LAU-7b, a novel oral drug candidate, was shown to control inflammation and stabilize CFTR protein in the epithelial membrane during inflammatory stress in preclinical models of CF.
METHODS:
A double-blind, randomized, placebo-controlled Phase 2 study was conducted to evaluate efficacy and safety of LAU-7b in adults with CF. LAU-7b or placebo was administered over 24 weeks as six 21-day treatment cycles each separated by 7 days. The primary efficacy endpoint was the absolute change from baseline in percent predicted forced expiratory volume in 1 second (ppFEV1) at 24 weeks.
RESULTS:
A total of 166 subjects received at least one dose of study drug (Intent-To-Treat population, ITT), of which 122 received ≥5 treatment cycles (Per-Protocol population, PP). Both treatment arms showed a mean lung function loss at 24 weeks of 1.18 ppFEV1 points with LAU-7b and 1.95 ppFEV1 with placebo, a 0.77 ppFEV1 (40 s) difference, p=0.345, and a 0.95 ppFEV1 (49 %) difference in the same direction in PP population, p=0.263. Primary analysis of mean ppFEV1 through 24 weeks showed differences of 1.01 and 1.23 ppFEV1, in the ITT (65 % less loss, p=0.067) and PP populations (78 % less loss, reaching statistical significance p=0.049), respectively. LAU-7b had an acceptable safety profile.
CONCLUSION:
Although the study did not meet its primary efficacy endpoint in the ITT population, LAU-7b was generally well tolerated and showed evidence of preservation of lung function to support further development.
2024-12-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
In-depth phytochemical profiling of Roscoea purpurea (Kakoli): Comparative UHPLC-MS/QToF and GC-MS/MS analysis of supercritical CO2 fluid - and conventional solvent - based extractive processes
Article
作者: Joshi, Monali ; Verma, Sudeep ; Balkrishna, Acharya ; Varshney, Yash ; Varshney, Anurag ; M, Priya Rani ; Nain, Pardeep
The remarkable biodiversity of medicinal plants worldwide highlights their significance in traditional and alternative medicine. Astavarga, a group of eight medicinal herbs from the Himalayan region of India, including Roscoea purpurea (commonly known as Kakoli), is esteemed in Ayurveda for its health-promoting and rejuvenating properties. In this comprehensive study, we aimed to develop and optimise robust UHPLC-MS/QToF (Ultra-high-performance liquid chromatography-mass spectrometry coupled with quadrupole time of flight) and GC-MS/MS (Gas chromatography-tandem mass spectrometry) methods to identify the phytochemicals in R. purpurea root hydromethanolic extract and essential oil. We also conducted a comparative assessment of supercritical fluid extraction and conventional solvent extraction methods for the first time in R. purpurea root, highlighting their relevance to the medicinal field. Using the UHPLC/MS-QToF method, we identified a total of fifty-six phytometabolites, while sixteen volatile constituents were discerned within the essential oil of R. purpurea by GC-MS/MS method. Among the volatile constituents, β-eudesmol (40.84 %), guaiac acetate (10.55 %), and γ-eudesmol (10.31 %) were emerged as the principal components. Our findings were further compared with the volatile constituents extracted via supercritical fluid extraction and conventional solvent extraction methods. Notably, our research unveiled the presence of a carotenoid metabolite, 15-methyl retinol, for the first time. Furthermore, our fatty acid analysis of the supercritical fluid extract revealed elevated levels of unsaturated fatty acids, particularly oleic and linoleic acids. The methods were validated in terms of system specificity also. The discovery of these well-recognised therapeutically active components in R. purpurea significantly enhances its potential, highlighting its unique profile among medicinal plants in the Himalayan region and its suitability for traditional Ayurveda.
23
项与 芬维A胺 相关的新闻（医药）2025-04-08
GROSSE POINTE FARMS, Mich., April 8, 2025 /PRNewswire/ -- SciTech Development, Inc., a clinical-stage oncology company pioneering innovative cancer therapeutics, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for "A Phase 1a/b Trial in Relapsed/Refractory Small Cell Lung Cancer (SCLC) to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension for Intravenous Infusion." This milestone greenlights SciTech to begin recruiting patients and initiates another Phase 1a/b clinical trial of ST-001, a novel nanoparticle drug designed to deliver fenretinide effectively to cancer cells.
The FDA's approval follows a thorough safety review, with the agency stating, "We have completed our safety review of your application and have concluded that you may proceed with your proposed clinical investigation of fenretinide phospholipid suspension (ST-001) for small cell lung cancer." This decision marks a significant step forward in SciTech's mission to address unmet needs in oncology, particularly for patients with relapsed or refractory SCLC, a notoriously aggressive disease with limited treatment options.
Leading the trial, as Principal Investigator, is Greg Kalemkerian, MD, a renowned thoracic oncologist at the University of Michigan. "Small cell lung cancer remains a formidable challenge with few effective therapies for patients who relapse or don't respond to initial treatment," said Dr. Kalemkerian. "ST-001 represents a promising approach, and I'm excited to oversee this trial to evaluate its safety and potential for SCLC patients who desperately need new options."
ST-001 nanoFenretinide leverages SciTech's patented drug delivery platform to overcome fenretinide's historical bioavailability challenges, delivering high doses intravenously with enhanced efficacy and reduced toxicity. The Phase 1a/b trial will assess the drug's safety, pharmacology, and maximum tolerated dose, paving the way for further development in SCLC and potentially other cancers.
Building on prior success in a Phase 1a trial for T-cell non-Hodgkin lymphoma - where ST-001 demonstrated favorable pharmacokinetics and early signs of efficacy - SciTech is preparing to launch the SCLC trial in Q2/3 2025. The company anticipates that this trial will further validate the drug's broad therapeutic potential.
"We are thrilled about the FDA's approval of our IND for ST-001 in SCLC," said Earle T. Holsapple, CEO of SciTech Development. "This is a pivotal moment that brings us closer to offering a transformative treatment option for patients facing this devastating disease. "Our team's dedication to advancing ST-001's potential through innovative nanotechnology is showing promising results, and we're eager to see its impact in the clinic."
About SciTech Development, Inc.
SciTech Development, Inc., headquartered in Grosse Pointe Farms, Michigan, is a clinical-stage pharmaceutical company focused on revolutionizing cancer treatment through its proprietary drug delivery platform. ST-001 nanoFenretinide, its lead candidate, combines fenretinide with biocompatible phospholipids to target hard-to-treat cancers, offering hope to patients worldwide.
For more information, please visit or contact:
Media Contact: David Schaffer | +1-727-278-8188 | [email protected]
Disclaimer: This press release contains forward-looking statements based on current expectations. Actual results may differ due to risks and uncertainties. SciTech undertakes no obligation to update these statements beyond legal requirements.
SOURCE SciTech Development, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
临床1期临床申请
2025-01-13
**Encouraging
Data from Accelerated Trial Supports Progress for T-cell Non-Hodgkin Lymphoma.**
DETROIT, Jan. 13, 2025 /PRNewswire/ -- SciTech Development, a clinical-stage pharmaceutical company specializing in oncology, is pleased to announce the initiation of the next stage of its clinical trial for their lead drug candidate,
ST-001 nanoFenretinide (ST-001)
. This milestone follows the successful completion of the accelerated safety and dose-escalation stage, where ST-001 demonstrated exceptional safety, tolerability, and pharmacokinetic performance.
Advancing the Phase 1a Trial with Clear Clinical Objectives
The continuation of the ST-001 clinical trial aims to achieve several critical clinical objectives:
Confirm that ST-001 achieves previously reported clinical response rates.
Determine the pharmacological profile of intravenous fenretinide delivered using SciTech's novel nanoparticle delivery system, designed for drugs with poor water solubility.
Determine the recommended treatment dose (RTD) to evaluate disease activity and response rates in the follow-on Phase 1b trial and the planned trial in Small Cell Lung Cancer.
"The success of our accelerated Phase 1a trial marks a pivotal milestone, driving ST-001 into the next critical stage of development," said Earle Holsapple, CEO of SciTech Development. "We are thrilled about the potential of ST-001 nanoFenretinide and its promise to transform treatment outcomes for patients battling cancers such as T-cell Non-Hodgkin Lymphoma."
About ST-001 nanoFenretinide
ST-001 nanoFenretinide is a patented nanoparticle IV formulation that combines the drug fenretinide with biocompatible phospholipids. This groundbreaking new investigational drug overcomes bioavailability challenges, enhances therapeutic efficacy, and minimizes toxicity in cancer patients. Powered by SciTech's advanced delivery platform, ST-001 enables rapid delivery of effective doses of fenretinide to cancer cells, marking a breakthrough in hard-to-treat cancers.
Encouraging Early Results in Phase 1a Accelerated Trial
During the accelerated stage of the trial, ST-001 achieved significant milestones:
Patient Enrollment is Complete for the accelerated stage of the clinical trial marking a significant accomplishment for patients with this rare disease.
Therapeutic Responses Observed: Patients demonstrated partial responses and stable disease, marking an important step for trial advancement.
Excellent Tolerability for ST-001 across all dose levels to date.
Outstanding Pharmacokinetics: The nanoparticle delivery platform overcame longstanding bioavailability challenges, ensuring efficient delivery of fenretinide to tissues.
Future Direction for ST-001 nanoFenretinide
Building on the success of the accelerated Phase 1a stage, the trial begins detailed evaluation of clinical activity and response rates in T-cell lymphomas. The trial is actively underway at nine renowned medical centers across the country. Click here to learn more about the locations and patient trial criteria. Additionally, a separate trial targeting Small Cell Lung Cancer utilizing ST-001 is scheduled to begin in Q2 2025.
About SciTech Development, Inc.
SciTech Development, Inc., headquartered in Michigan, is an oncology focused, clinical-stage pharmaceutical company led by a world-class team. SciTech is committed to developing innovative, effective, and affordable cancer therapeutics that address unmet medical needs to bring hope to patients around the globe. To learn about SciTech and our latest advancements, please visit .
Read the latest Press Release announcing "Promising Preliminary Results from the Phase 1a Accelerated Trial".
Company Contact:
David Schaffer
Investor Relations
[email protected]
(727) 278-8118
SOURCE SciTech Development, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
临床1期
2024-12-19
A case study on how a pharmaceutical company specializing in cystic fibrosis treatments turned to DelveInsight for comprehensive analysis and insights into the digital cystic fibrosis landscape in the UK. DelveInsight identified key Digital Opinion Leaders (DOLs) and synthesized their opinions, enabling the client to strategically leverage these insights for drug development, marketing, and patient advocacy, ensuring a competitive edge in the cystic fibrosis market.
LAS VEGAS, Dec. 19, 2024 /PRNewswire/ -- DelveInsight, a leader in healthcare competitive intelligence and consulting company, published a success study on Digital Opinion Leader (DOL) Analysis in the
Cystic Fibrosis Market
. A pharmaceutical company specializing in cystic fibrosis treatments approached DelveInsight to conduct an in-depth analysis of DOLs in the UK. The client sought to identify key digital influencers and understand their perspectives on cystic fibrosis treatments, leveraging these insights to inform drug development, marketing strategies, and patient advocacy efforts.
Cystic fibrosis is a life-limiting autosomal recessive genetic disorder that primarily affects the lungs and digestive system, caused by mutations in the CFTR gene. According to DelveInsight's latest Cystic Fibrosis Market and Epidem Forecast Report, the estimated total diagnosed prevalent cases of cystic fibrosis in the
7MM in
2023 were
~68K cases. The
UK had the highest number of
diagnosed cystic fibrosis cases, with nearly
11K, followed by France with
7.5K and Germany with
7K. In the
EU4 and the UK, the cystic fibrosis market size was nearly
USD 7 billion, accounting for almost
39.4% of the total
7MM market size in
2023. This is expected to increase
significantly by 2034.
Download the Sample Report to Explore Future Trends in the
Cystic Fibrosis Market
In the field of cystic fibrosis,
DOLs play a significant role in shaping perceptions and influencing the direction of treatment, policy, and patient care. These are influential healthcare professionals or researchers who have an active online presence and contribute to discussions, research, and advocacy. For pharmaceutical companies developing cystic fibrosis treatments, understanding the DOL landscape is crucial for gaining insights into market dynamics and stakeholder perceptions and identifying strategic opportunities for drug development, marketing, and patient advocacy.
Several medications have been approved to manage cystic fibrosis, with therapies targeting the CFTR protein to correct its defects. One of the most groundbreaking treatments is TRIKAFTA, a combination of
elexacaftor, tezacaftor, and ivacaftor, which has revolutionized cystic fibrosis treatment by improving lung function in patients with specific genetic mutations. Other notable drugs include
SYMDEKO (tezacaftor/ivacaftor) and ORKAMBI (lumacaftor/ivacaftor), which also target the CFTR protein. These therapies aim to address the root cause of the disease, improving symptoms and quality of life for patients. However, despite these advancements, the current treatment landscape still faces challenges, such as variability in treatment efficacy and accessibility to newer therapies for certain patient populations.
The pipeline for cystic fibrosis treatments continues to evolve, with several promising drugs in the cystic fibrosis pipeline.
Ensifentrine (Verona Pharmaceuticals) is a dual inhibitor of the enzymes responsible for inflammation and mucus production in the lungs, showing potential as an add-on therapy for patients with CF.
VX-121/TEZ/VX-561 (Vertex Pharmaceuticals) is another exciting treatment, combining triple therapy to enhance CFTR function and improve lung function.
LAU-7b (Laurent Pharmaceuticals Inc.) aims to restore CFTR function and reduce inflammation.
Lonodelestat (Pari Pharma GmbH) is being investigated for its ability to reduce neutrophil elastase and inflammation in the lungs of CF patients. These drugs, if successful, could significantly improve treatment options and outcomes for CF patients.
Several companies are at the forefront of developing treatments for cystic fibrosis.
Eloxx Pharmaceuticals, Inc. focuses on treatments that aim to restore protein function in CF patients with specific genetic mutations. Vertex Pharmaceuticals is a leader in the CF market, with therapies like
TRIKAFTA and ongoing pipeline developments.
Santhera Pharmaceuticals is exploring potential treatments to address pulmonary issues in CF patients.
DelveInsight helped the client by curating insights from the digital cystic fibrosis landscape and analyzing the opinions of key digital influencers. By identifying and analyzing these DOLs, DelveInsight provided actionable insights and strategic recommendations for the client. The company gained a deeper understanding of the market dynamics, stakeholder perceptions, and the evolving digital landscape surrounding cystic fibrosis. These insights were invaluable for informing drug development strategies, understanding the gaps, patient burden,, and patient advocacy initiatives. Armed with comprehensive information on DOLs and their impact, the client was better equipped to make informed decisions, enhance patient engagement, and improve the overall market approach for cystic fibrosis treatments.
Our client approached us with multiple objectives:
Understand the DOL Landscape in the UK for cystic fibrosis.
Identify Key Digital Opinion Leaders influencing discussions about cystic fibrosis.
Analyze the Opinions of DOLs on treatment options and emerging therapies.
Leverage Insights to refine drug development, marketing strategies, and patient advocacy efforts.
Outcome of DelveInsight's Digital Opinion Leader Analysis:
We identified and profiled key digital opinion leaders (DOLs) in the UK cystic fibrosis community, focusing on those with strong online presence, high engagement, and CF expertise.
Through content analysis, we gained insights into opinions, trends, and key areas like treatment, patient care, advocacy, and research within the CF community.
We mapped the CF digital ecosystem, highlighting connections and interactions between DOLs and stakeholders revealing network dynamics and engagement patterns.
We assessed the impact of DOLs using metrics like follower count, engagement rate, and content virality, helping clients prioritize engagement strategies and collaborations.
DelveInsight specializes in comprehensive Key Opinion Leader (KOL) and Digital Opinion Leader (DOL) opinion analysis, offering deep insights into industry trends, expert perspectives, and influencer dynamics. Our expertise enables clients to identify and understand the nerve of the trends by providing analysis through the most impactful thought leaders and digital influencers. By leveraging our tailored strategies and data-driven approaches, we help businesses strengthen their approach, refine decision-making, and amplify their market impact.
Connect with us today to explore how we can support your specific needs and discuss opportunities for strategic engagement.
Request a Proposal Now
!
Why Choose DelveInsight?
DelveInsight offers comprehensive expertise in the respiratory disease domain, providing in-depth market research, consulting services, and pipeline analysis tailored to the evolving needs of the industry. With a sharp focus on respiratory conditions, DelveInsight delivers robust reports covering emerging therapies, market trends, competitive landscapes, and unmet needs. DelveInsight's respiratory-specific solutions empower stakeholders to make data-driven decisions, optimize their R&D efforts, and seize growth opportunities in the dynamic and rapidly advancing respiratory disease market.
Market Assessment Services in the Genetic Disorders Segment, DelveInsight, provide a 360-degree view of the market landscape. Our expertise includes
epidemiology-based market forecasts up to 2034, offering precise insights into current and future market share uptake of emerging therapies. These forecasts, combined with detailed analyses of emerging trends, competitive dynamics of the pipeline therapies, and unmet needs, enable stakeholders to strategize effectively and identify growth opportunities. Whether it's the pipeline analysis, pricing strategies, or competitive benchmarking, DelveInsight delivers actionable intelligence tailored to your goals.
Contact us Today to discuss how our services can drive success in your endeavors within the genetic disorder market.
Competitive Intelligence Services Tailored to Genetic Disorder Domain: DelveInsight's competitive intelligence services provide real-time, accurate insights across the different therapeutic domains and genetic disorders being one of our fortes, providing detailed insights into advancements across rare and inherited conditions such as cystic fibrosis, Duchenne muscular dystrophy, and sickle cell anemia etc to name a few. Our services analyze competitors' pipelines, clinical trial progress, gene and cell therapy innovations, and market entry strategies, as well as regulatory updates and patent landscapes specific to genetic disorders. This intelligence enables stakeholders to identify emerging threats, uncover growth opportunities, and develop targeted strategies to remain competitive in this evolving therapeutic area.
Connect with us today to explore how we can help you succeed in the genetic disorders market.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform , PharmDelve
.
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo:
SOURCE DelveInsight Business Research, LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
上市批准
100 项与 芬维A胺 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新冠肺炎后遗症 | 临床3期 | 加拿大 | 2023-11-20 | |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-29 | |
| BRCA突变阳性乳腺癌 | 临床3期 | 意大利 | 2009-12-01 | |
| HR阳性乳腺癌 | 临床3期 | 美国 | 1995-10-01 | |
| 乳腺癌 | 临床3期 | - | - | |
| 乳腺癌 | 临床3期 | - | - | |
| 登革热 | 临床2期 | 美国 | 2024-09-05 | |
| 囊性纤维化 | 临床2期 | 美国 | 2018-11-05 | |
| 囊性纤维化 | 临床2期 | 澳大利亚 | 2018-11-05 | |
| 囊性纤维化 | 临床2期 | 加拿大 | 2018-11-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | - | 憲醖網膚願糧築齋糧衊(簾鹹鏇窪窪繭憲蓋獵醖) = earlier-than-anticipated stable disease and partial responses - one initial and one confirmed. 網選觸窪構網蓋鏇鹽願 (鏇淵鑰鑰淵膚鹹鹹鏇衊 ) 更多 | 积极 | 2024-12-03 | |||
临床2期 | 166 | (LAU-7b) | 構觸蓋築顧鏇膚顧顧廠(膚壓遞淵顧衊衊觸範積) = 繭繭淵廠鏇糧願觸夢廠 醖膚鬱築鑰餘簾廠鏇積 (獵廠顧窪顧鹽夢膚鏇窪, 選壓網範築蓋鏇鏇衊獵 ~ 範獵醖鏇鑰鬱淵窪遞鏇) 更多 | - | 2024-10-09 | ||
Placebo oral capsule (Placebo) | 構觸蓋築顧鏇膚顧顧廠(膚壓遞淵顧衊衊觸範積) = 願獵鬱繭獵網簾積製構 醖膚鬱築鑰餘簾廠鏇積 (獵廠顧窪顧鹽夢膚鏇窪, 簾醖積積製壓鹹觸襯鹹 ~ 網範壓繭獵製餘糧鏇獵) 更多 | ||||||
临床1期 | 16 | Fenretinide | 選廠壓齋衊膚築窪廠廠(網鹽淵艱鏇積顧築積遞) = 觸壓願餘鬱窪築鑰壓壓 積膚憲鏇製廠餘襯構鹹 (齋觸憲築鑰繭顧蓋鬱鹹 ) | 不佳 | 2023-08-01 | ||
临床2期 | 166 | 壓夢製簾齋襯簾鏇鏇鑰(齋襯繭簾簾膚網醖憲糧): difference = 1.23, P-Value = 0.0486 | 积极 | 2022-11-03 | |||
Placebo | |||||||
临床2期 | 21 | (A- Fenretinide) | 廠獵壓鹽艱衊簾蓋網憲(餘選淵積遞壓網餘獵構) = 鑰鑰繭獵顧製築鑰艱淵 築鏇餘餘願鬱蓋艱衊窪 (顧糧積積衊積積網窪憲, 壓簾窪積製艱範願願願 ~ 醖遞築鹹網鑰蓋夢餘選) 更多 | - | 2021-02-10 | ||
placebo (B-Placebo) | 廠獵壓鹽艱衊簾蓋網憲(餘選淵積遞壓網餘獵構) = 觸糧鑰艱膚鑰憲壓築築 築鏇餘餘願鬱蓋艱衊窪 (顧糧積積衊積積網窪憲, 觸齋鏇鬱糧鏇築鬱網窪 ~ 衊廠築憲夢顧蓋餘醖衊) 更多 | ||||||
临床1/2期 | 32 | 衊壓壓淵鑰壓窪蓋襯積(糧窪鹽蓋夢淵顧製繭蓋) = No dose-limiting toxicities were observed. 鑰鹹廠製廠醖蓋願廠鏇 (鹹繭淵鑰夢鏇構襯廠範 ) 更多 | 积极 | 2017-02-01 | |||
临床2期 | 23 | 窪廠夢蓋餘繭鬱窪積憲 = 鬱鬱鹽憲鏇積觸艱夢構 網選選顧鹹壓網醖繭觸 (積蓋鬱餘餘醖獵廠糧膚, 願衊艱觸襯鹽積鹽淵襯 ~ 願廠廠壓簾顧廠壓簾窪) 更多 | - | 2015-03-06 | |||
临床1/2期 | 32 | (Fenretinide and Rituximab) | 繭衊積網鏇壓衊構襯繭 = 餘廠範襯構襯鹹鏇壓積 襯壓積襯選築壓憲鹽壓 (餘憲選壓壓簾鏇鑰顧繭, 鹹範鹽衊築遞窪願餘餘 ~ 蓋夢膚廠壓網願繭艱壓) 更多 | - | 2014-10-06 | ||
(Fenretinide and Rituximab (Rituximab Naive)) | 鬱膚壓顧醖膚襯鏇夢鹹 = 憲襯壓鑰壓遞遞積襯遞 膚範選膚鬱壓壓構獵鏇 (艱廠窪膚鬱夢醖憲觸製, 窪餘簾襯膚鏇製簾繭鏇 ~ 製獵餘壓夢糧觸網膚夢) | ||||||
临床1期 | 80 | 壓獵窪遞淵願襯糧鏇膚(糧製窪鹽範糧願選窪遞) = 襯壓製積夢淵鹹夢繭獵 鹹糧醖壓鏇簾鏇積鏇糧 (積製簾鏇襯醖顧壓築窪, 1.35 ~ 36.9+) 更多 | - | 2014-05-20 | |||
憲選觸齋範網鹹遞築願(齋願夢繭鑰襯壓製構餘) = 鬱願憲顧蓋願窪築積獵 蓋鏇膚醖築蓋範憲壓餘 (廠製繭膚鑰簾簾繭鹽憲, 14.6 ~ 22.1) | |||||||
临床1期 | 25 | 鏇糧鹽壓構顧觸襯範憲(淵憲糧膚獵壓繭憲醖窪) = Reversible hypertriglyceridemia related to the intralipid vehicle accounted for 6/7 DLTs 顧衊窪蓋鬱範鏇齋鑰顧 (遞蓋選選憲鹹選遞夢鹽 ) | - | 2012-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用